Xyzal 0,5 mg/ml oralna otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

xyzal 0,5 mg/ml oralna otopina

ucb pharma s.a., allée de la recherche 60, anderlecht (bruxelles), belgija - levocetirizindiklorid - oralna otopina - 0,5 mg/ml - urbroj: 1 ml oralne otopine sadrži 0,5 mg levocetirizindiklorida

Cimzia Europska Unija - hrvatski - EMA (European Medicines Agency)

cimzia

ucb pharma sa - Цертолизумаб pegol - crohn disease - imunosupresivi - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.